CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 590 enrolled
Drug / intervention
Lubiprostone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00380250
NCT00380250Phase 3Completed
CompareCT.gov

Phase 3, 12-Week, Multicenter, Double-Blind, Randomized, Efficacy and Safety Study of Lubiprostone for the Treatment of Irritable Bowel Syndrome With Constipation

Sucampo Pharma Americas, LLC·interventional·Posted Sep 25, 2006·Updated Nov 15, 2019

In Brief

A Phase 3 clinical trial evaluating Lubiprostone and Placebo for Irritable Bowel Syndrome With Constipation. Completed, enrolled 590 participants.

Detailed Summary

The primary purpose of this study is to evaluate the efficacy and safety of administration of lubiprostone in patients with irritable bowel syndrome with constipation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIrritable Bowel Syndrome With Constipation
Countries--
CollaboratorsTakeda

Timeline

Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 25, 2006
Enrollment StartMay 1, 2005
Study CompletionJul 1, 2006
TodayJul 2, 2026
Posted 19.8 years ago

Interventions

Lubiprostonedrug

Placebodrug